<DOC>
	<DOCNO>NCT01720680</DOCNO>
	<brief_summary>- Title : Open-label , prospective exploratory study assess effect AlphaCore® device central peripheral airway dimension patient COPD . - Indication : COPD patient - Study Design : Open-label , prospective design - Study Phase : II - Test treatment duration : 1 day - Test treatment : AlphaCore® device - Dosage regimen : 1 session stimulation 90 second - Patient number : 10 evaluable patient COPD - Patient age : ≥ 18 year - Sex : male female - Primary objective : The evaluation effect AlphaCore® device central peripheral airway dimension Computational Fluid Dynamics ( CFD ) . - Secondary objective : The assessment effect AlphaCore® device lung function ( spirometry , diffusion resistance ) patient report outcome ( PRO ` ) .</brief_summary>
	<brief_title>Prospective Exploratory Study Assess Effects AlphaCore® Device Patients With COPD</brief_title>
	<detailed_description />
	<criteria>Patients document diagnosis COPD Male female patient age ≥18 year Patients cooperative attitude treat AlphaCore® device Patients take anticholinergic Female patient childbearing potential confirm use contraception method study Written inform consent obtain Pregnant lactate female female risk pregnancy screen willing use appropriate contraception method study period Inability carry pulmonary function test Patients uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study Patients electrical and/or neurostimulator device ( e.g . cardiac pacemaker , vagal neurostimulator , defibrillator , cochlear implant , … ) Patients abscess infection lesion ( incl . lymphadenopathy ) therapy head placement site Patients compromise cervical anatomy ( scar , infection suspect carotid artery disease ) cervical vagotomy Patients history carotid endarterectomy vascular neck surgery right side Patients coagulopathy , irregular heart rhythm pressor medication Patients unlikely comply protocol unable understand nature , scope possible consequence study Patients receive investigational new drug within last 4 week prior screen visit Patients treat nonpermitted concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Functional Imaging</keyword>
	<keyword>Patient Reported Outcome ( PRO )</keyword>
	<keyword>Lung Function</keyword>
	<keyword>AlphaCore</keyword>
	<keyword>Computational Fluid Dynamics</keyword>
</DOC>